At a glance
ClinicalIndex Comparison RecordPhase 2Active· 16 enrolled
Drug / intervention
MK-3475 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating MK-3475 and Gemcitabine for Carcinoma, Non-Small-Cell Lung. Active but no longer recruiting, targeting 16 participants across 2 sites.
Detailed Summary
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine. The study will also try to identify the best dose of MK-3475 to give in combination with gemcitabine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
Timeline
Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedApr 2015
Enrollment StartJul 2015
Primary CompletionJan 2019
TodayJul 2026
Study CompletionDec 2026
First PostedApr 21, 2015
Enrollment StartJul 20, 2015
Primary CompletionJan 9, 2019
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.2 years ago
Interventions
MK-3475drug
Investigational drug.
Gemcitabinedrug
Standard care drug.